Filter By Category
Archives
Share on -
AZERCABTAGENE ZAPRELEUCEL
Generic Name: AZERCABTAGENE ZAPRELEUCEL
ABSTRACT -
Azercabtagene zapreleucel, also known as azer-cel or PBCAR0191, is an investigational allogeneic chimeric antigen receptor T-cell therapy directed against CD19. It is manufactured from donor T cells modified to express a CD19-directed CAR and is being studied for B-cell malignancies and immune-mediated neurologic diseases. As a living cellular product, it has no single small-molecule chemical structure. Development/regulatory status: Investigational.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE-
- Dose must follow the clinical-trial protocol or approved cellular-therapy label.
- Administration typically follows lymphodepleting chemotherapy and occurs as an intravenous infusion in a specialist centre.
- Cell dose is defined by viable CAR-positive T-cell number and product specifications.
- Premedication, bridging therapy, and repeat dosing are protocol-specific.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Cytokine release syndrome with fever, hypotension, or hypoxia
- Immune-effector-cell-associated neurotoxicity syndrome, confusion, tremor, seizures, or encephalopathy
- Cytopenias, infection risk, febrile neutropenia, or hypogammaglobulinaemia
- Graft-versus-host disease risk with allogeneic T cells
- Tumour lysis syndrome, fatigue, nausea, or infusion reactions
ALLERGIC REACTIONS -
Hypersensitivity to azercabtagene zapreleucel or related compounds/products may occur. Symptoms may include:
- Infusion reaction or injection-site reaction where applicable
- Rash or urticaria
- Bronchospasm or breathing difficulty
- Facial, lip, tongue, or throat swelling
- Anaphylaxis
Important: Patients who develop an allergic reaction to azercabtagene zapreleucel should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
- Corticosteroids or immunosuppressants may reduce cellular activity unless used for toxicity management.
- Live vaccines should generally be avoided during immune suppression and B-cell aplasia.
- Myelosuppressive chemotherapy, biologics, and investigational agents require specialist review.
- Patients should disclose all medicines, vaccines, and supplements.
PREAUTIONS–
- Administer only in centres able to manage CRS, neurotoxicity, infections, and intensive supportive care.
- Monitor neurologic status, blood counts, inflammatory markers, organ function, and infection prophylaxis.
- Confirm product identity, viability, chain of custody, and release criteria before infusion.
WARNINGS –
- CAR T-cell therapy can cause life-threatening CRS, neurotoxicity, infection, and prolonged cytopenias.
- Patients require close observation after infusion and long-term follow-up.
- Keep product handling within regulated cell-therapy systems.
Share on -
. Developed by